TCL1A and neoplasm: To evaluate the in vivo anti-tumor effect of PRT382 we first confirmed that the Eμ-PRMT5/TCL1 bulk tumor population was amenable to adoptive transfer into immunocompetent C57BL/6J syngeneic mice.